| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,976 | -13,446 |
| Depreciation and amortization | 309 | 204 |
| Stock-based compensation | 1,017 | 741 |
| Non-cash lease expense | 153 | 114 |
| Fixed assets write-off | 0 | 0 |
| R&d tax credit incentive receivable | 411 | 241 |
| Prepaid expenses and other assets | -1,062 | -412 |
| Accounts payable | 174 | 933 |
| Accrued compensation expenses | 14 | 13 |
| Accrued expenses | 57 | 20 |
| Net cash used in operating activities | -17,601 | -11,250 |
| Purchases of property and equipment | 899 | 76 |
| Net cash used in investing activities | -899 | -76 |
| Issuance of common stock and warrants in connection with the securities purchase agreement, net of issuance costs | 0 | 0 |
| Issuance of common stock in connection with the 2025 private sales transaction, net of issuance costs | 2,593 | - |
| Gross proceeds from insurance premium loan | 355 | - |
| Issuance of common stock and warrants in connection with the sales agreement, net of issuance costs | - | 0 |
| Payments on insurancepremiumloan | -237 | -237 |
| Net issuance costs in connection with the sales agreement | - | 28 |
| Net proceeds from issuance of common stock in connection with the sales agreement, net of issuance costs | -28 | - |
| Net cash provided by financing activities | 2,683 | -265 |
| Effect of exchange rate changes on cash and cash equivalents | 93 | 33 |
| Net decrease increase in cash, cash equivalents and restricted cash | -15,724 | -11,558 |
| Cash and cash equivalents at beginning of period | 19,690 | - |
| Cash and cash equivalents at end of period | 3,966 | - |
Vivani Medical, Inc. (VANI)
Vivani Medical, Inc. (VANI)